Zeta H Pylori Antibody Cocktail. Zeta’s recombinant rabbit antibody cocktail of two well-characterized monoclonal antibodies, recognizes H pylori (Helicobacter pylori), which is known to cause peptic ulcers and chronic gastritis in human. H pylori is associated with duodenal ulcers and may be involved in development of adenocarcinoma and low-grade lymphoma of mucosa associated lymphoid tissue in the stomach. The Zeta antibody cocktail reacts with H pylori on the surface and in the cytoplasm of epithelial cells of stomach biopsies. Studies have shown that H pylori plays an important role in the etiology of chronic active gastritis and the development of peptic ulcer disease. Immunohistochemistry can provide rapid detection of this bacterium.
Gastric cancer is the fifth most common cancer and the fifth leading cause of cancer-related death worldwide and is associated with Helicobacter pylori (H pylori) infection. Stomach cancer accounts for about 1.5% of all new cancers diagnosed in the US each year. Helicobacter pylori (H pylori) is the most common cause of gastric ulcer; and is associated with gastric cancer. H pylori infection affects around half of the world’s population leading to a variety of gastric problems and is mostly present in asymptomatic form. Although about 20% of people infected with H pylori develop preneoplastic gastric lesions in later stages of their life, around 2% of infected individuals develop gastric cancer.
H pylori infection is determined by complex interaction between the host genetics, its environment, and virulence factors of infecting strain. The presence of certain major virulence factors including cytotoxin-associated gene A (CagA), vacuolating cytotoxin (VacA), and outer inflammatory protein A (OipA) plays a significant role in triggering gastric cancer. These factors of H pylori make it a potent carcinogen. Helicobacter pylori Oncogenicity: Mechanism, Prevention, and Risk Factors – Muzaheed – 2020 – The Scientific World Journal – Wiley Online Library
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.